Cytori Therapeutics Inc (NASDAQ:CYTX) major shareholder Bank Sa Swissquote sold 72,630 shares of the company’s stock in a transaction on Thursday, January 11th. The stock was sold at an average price of $0.34, for a total transaction of $24,694.20. Following the completion of the transaction, the insider now owns 5,496,655 shares of the company’s stock, valued at $1,868,862.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
Bank Sa Swissquote also recently made the following trade(s):
- On Tuesday, January 9th, Bank Sa Swissquote sold 100,000 shares of Cytori Therapeutics stock. The shares were sold at an average price of $0.38, for a total transaction of $38,000.00.
Shares of Cytori Therapeutics Inc (NASDAQ:CYTX) traded up $0.06 during trading hours on Friday, hitting $0.42. 4,316,600 shares of the stock traded hands, compared to its average volume of 3,141,875. The company has a market capitalization of $15.45, a P/E ratio of -0.47 and a beta of 3.21. Cytori Therapeutics Inc has a 52-week low of $0.22 and a 52-week high of $2.13.
Cytori Therapeutics (NASDAQ:CYTX) last issued its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.16) by $0.02. Cytori Therapeutics had a negative net margin of 367.33% and a negative return on equity of 228.21%. The firm had revenue of $1.77 million during the quarter, compared to the consensus estimate of $2.04 million. During the same period in the prior year, the firm posted ($0.26) earnings per share. equities research analysts forecast that Cytori Therapeutics Inc will post -0.62 earnings per share for the current year.
Several research firms have issued reports on CYTX. B. Riley restated a “hold” rating on shares of Cytori Therapeutics in a research report on Tuesday, November 7th. Zacks Investment Research lowered shares of Cytori Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, November 9th. Finally, Maxim Group set a $5.00 price objective on shares of Cytori Therapeutics and gave the company a “buy” rating in a research note on Thursday, October 19th.
A hedge fund recently raised its stake in Cytori Therapeutics stock. Vanguard Group Inc. increased its stake in Cytori Therapeutics Inc (NASDAQ:CYTX) by 81.9% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 612,304 shares of the biotechnology company’s stock after buying an additional 275,653 shares during the period. Vanguard Group Inc. owned 1.89% of Cytori Therapeutics worth $674,000 at the end of the most recent reporting period. 7.41% of the stock is owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY NOTICE: This news story was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this news story on another domain, it was copied illegally and republished in violation of international copyright and trademark legislation. The legal version of this news story can be read at https://www.dispatchtribunal.com/2018/01/19/cytori-therapeutics-inc-cytx-major-shareholder-bank-sa-swissquote-sells-72630-shares-of-stock.html.
Cytori Therapeutics Company Profile
Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.
Receive News & Ratings for Cytori Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.